The potential medication being studied is called ibuzatrelvir. It is an oral antiviral (taken by mouth) designed to prevent the virus that causes COVID-19 from multiplying in the body. Ibuzatrelvir may help people with weakened immune systems get better and stay out of the hospital.
This clinical trial will evaluate ibuzatrelvir when given alone and in combination with a medication called remdesivir. Remdesivir is a prescription antiviral approved by the US Food and Drug Administration (FDA) for adults who have mild-to-moderate COVID-19 and are at increased risk for progression to severe COVID-19.